NCT05279001View on ClinicalTrials.gov

A Safety and Tolerability Study of Jaktinib

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions
Myelofibrosis
Interventions
DRUG

Jaktinib Hydrochloride Tablet

Orally administered, twice a day

Trial Locations (1)

44718

RECRUITING

Site 01, Canton

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY